{
  "extraction_date": "2025-12-23",
  "condition": "CANCER",
  "phase": "3",
  "priority": "Expansion",
  "total_studies": 9,
  "studies": [
    {
      "study_id": "CT_NCT03307200",
      "study_type": "Clinical Trial",
      "condition": "CANCER",
      "study_title": "Unmet Supportive Care Needs in Bladder Cancer Patients Undergoing Radical Cystectomy",
      "citation": "ClinicalTrials.gov NCTNCT03307200",
      "publication_year": 2021,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabis mentioned in study text",
        "delivery_method": "various",
        "dosing_information": "Phase N/A",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Change in Unmet supportive care needs"
        ],
        "outcome_measures": [
          "Change in Unmet supportive care needs"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT03307200",
        "enrollment": 90,
        "phase": "N/A",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT03307200"
      }
    },
    {
      "study_id": "CT_NCT05684939",
      "study_type": "Clinical Trial",
      "condition": "CANCER",
      "study_title": "Relation Between Substance Use and Pain, in Patients Suffering or Surviving From Cancer and Followed in France",
      "citation": "ClinicalTrials.gov NCTNCT05684939",
      "publication_year": 2023,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabis mentioned in study text",
        "delivery_method": "various",
        "dosing_information": "Phase N/A",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "substance use"
        ],
        "outcome_measures": [
          "substance use"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT05684939",
        "enrollment": 2010,
        "phase": "N/A",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT05684939"
      }
    },
    {
      "study_id": "CT_NCT01812616",
      "study_type": "RCT",
      "condition": "CANCER",
      "study_title": "A Safety Study of Sativex Compared With Placebo (Both With Dose-intense Temozolomide) in Recurrent Glioblastoma Patients",
      "citation": "ClinicalTrials.gov NCTNCT01812616",
      "publication_year": 2016,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Sativex",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE1",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Incidence of Adverse Events as a Measure of Patient Safety."
        ],
        "outcome_measures": [
          "Incidence of Adverse Events as a Measure of Patient Safety."
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT01812616",
        "enrollment": 21,
        "phase": "PHASE1",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT01812616"
      }
    },
    {
      "study_id": "CT_NCT04447846",
      "study_type": "RCT",
      "condition": "CANCER",
      "study_title": "Novel Cognitive Treatment Targets for Epidiolex in Sturge- Weber Syndrome",
      "citation": "ClinicalTrials.gov NCTNCT04447846",
      "publication_year": 2022,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabidiol",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE2",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "List Sorting Working Memory Test"
        ],
        "outcome_measures": [
          "List Sorting Working Memory Test"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT04447846",
        "enrollment": 11,
        "phase": "PHASE2",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT04447846"
      }
    },
    {
      "study_id": "CT_NCT00553059",
      "study_type": "RCT",
      "condition": "CANCER",
      "study_title": "Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer",
      "citation": "ClinicalTrials.gov NCTNCT00553059",
      "publication_year": 2014,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "dronabinol",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE3",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Number of Participants With Total Protection in the Acute, Delayed and Overall Periods"
        ],
        "outcome_measures": [
          "Number of Participants With Total Protection in the Acute, Delayed and Overall Periods"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT00553059",
        "enrollment": 62,
        "phase": "PHASE3",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT00553059"
      }
    },
    {
      "study_id": "CT_NCT05388058",
      "study_type": "RCT",
      "condition": "CANCER",
      "study_title": "Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy",
      "citation": "ClinicalTrials.gov NCTNCT05388058",
      "publication_year": 2023,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Cannabidiol",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE2",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Change in chemotherapy-induced peripheral neuropathy (CIPN)"
        ],
        "outcome_measures": [
          "Change in chemotherapy-induced peripheral neuropathy (CIPN)"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT05388058",
        "enrollment": 30,
        "phase": "PHASE2",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT05388058"
      }
    },
    {
      "study_id": "CT_NCT00314808",
      "study_type": "RCT",
      "condition": "CANCER",
      "study_title": "A Pilot Study of Dronabinol for Adult Patients With Primary Gliomas",
      "citation": "ClinicalTrials.gov NCTNCT00314808",
      "publication_year": 2012,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Dronabinol",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE1",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Tolerability Rate",
          "Unacceptable Toxicity Rate"
        ],
        "outcome_measures": [
          "Tolerability Rate",
          "Unacceptable Toxicity Rate"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT00314808",
        "enrollment": 33,
        "phase": "PHASE1",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT00314808"
      }
    },
    {
      "study_id": "CT_NCT01812603",
      "study_type": "RCT",
      "condition": "CANCER",
      "study_title": "A Safety Study of Sativex in Combination With Dose-intense Temozolomide in Patients With Recurrent Glioblastoma",
      "citation": "ClinicalTrials.gov NCTNCT01812603",
      "publication_year": 2016,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Sativex",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE1",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "The incidence of adverse events in patients receiving Sativex in combination with dose-intense Temozolomide in the open-label phase of the study"
        ],
        "outcome_measures": [
          "The incidence of adverse events in patients receiving Sativex in combination with dose-intense Temozolomide in the open-label phase of the study"
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT01812603",
        "enrollment": 6,
        "phase": "PHASE1",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT01812603"
      }
    },
    {
      "study_id": "CT_NCT03984214",
      "study_type": "RCT",
      "condition": "CANCER",
      "study_title": "Efficacy and Safety of Dronabinol in the Improvement of Chemotherapy-induced and Tumor-related Symptoms in Advanced Pancreatic Cancer",
      "citation": "ClinicalTrials.gov NCTNCT03984214",
      "publication_year": 2024,
      "journal": "ClinicalTrials.gov",
      "intervention": {
        "cannabis_type": "cannabis/cannabinoids",
        "cannabinoid_profile": "Dronabinol in Oral Dosage Form",
        "delivery_method": "various",
        "dosing_information": "Phase PHASE3",
        "treatment_duration": "clinical trial duration"
      },
      "outcomes": {
        "key_findings": [
          "Standardized area under the curve of the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C30 symptom summary score over the on-treatment period."
        ],
        "outcome_measures": [
          "Standardized area under the curve of the European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire (QLQ)-C30 symptom summary score over the on-treatment period."
        ],
        "adverse_events": [],
        "evidence_rating": "medium",
        "confidence_level": "medium"
      },
      "metadata": {
        "nct_id": "NCT03984214",
        "enrollment": 109,
        "phase": "PHASE3",
        "source": "ClinicalTrials.gov",
        "url": "https://clinicaltrials.gov/study/NCT03984214"
      }
    }
  ],
  "expansion_metadata": {
    "clinicaltrials_gov_added": 9,
    "pubmed_added": 0,
    "total_added": 9,
    "expansion_date": "2025-12-23T23:42:18.482351"
  }
}